3 active not recruiting, 2 withdrawn, 1 completed. 5 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 3, Withdrawn 2 |
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Withdrawn 1 |
Follow Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma: new trials by email Literature Review of Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma trials Research Report on Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer Bevacizumab, Biospecimen Collection, Computed Tomography - Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2025-10-31 | 2025-06-03 | |
| Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Biopsy, Biospecimen Collection, Computed Tomography - Fallopian Tube Carcinosarcoma, Primary Peritoneal Carcinosarcoma | Phase 1 / Phase 2 | Active not recruiting | Mayo Clinic | 38 | 2023-09-28 | 2026-09-21 |
| Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy Computed Tomography, Copanlisib Hydrochloride, Magnetic Resonance Imaging - Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2022-06-30 | 2023-09-26 | |
| Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients Lenvatinib, Pembrolizumab - High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 30 | 2021-11-09 | 2026-08-10 |
| Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents Biospecimen Collection, Cediranib Maleate, Computed Tomography - Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 120 | 2021-06-10 | 2026-10-22 |
| Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer Olaparib, Onalespib - Metastatic High Grade Fallopian Tube Serous Adenocarcinoma, Metastatic Malignant Solid Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 28 | 2017-05-19 | 2023-04-26 |
Breast Neoplasms (1) · Fallopian Tube Neoplasms (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Neoplasms (2) · Neoplasms by Site (2) · Adnexal Diseases (1) · Breast Diseases (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Fallopian Tube Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Genital Diseases, Female (1) · Genital Neoplasms, Female (1) · Gonadal Disorders (1) · Neoplastic Processes (1) · Ovarian Diseases (1)
Magnetic Resonance Spectroscopy (4) · Paclitaxel (3) · Specimen Handling (3) · Taxes (3) · olaparib (3) · Disulfides (2) · Doxorubicin (2) · Immunoglobulin G (2) · Topotecan (2) · liposomal doxorubicin (2) · pembrolizumab (2) · (2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone (1) · ASTX-660 (1) · Bevacizumab (1) · Biopsy (1)
National Cancer Institute (NCI) (4) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1)
United States (5) · Puerto Rico (1)
Panagiotis A Konstantinopoulos (2) · Amir A Jazaeri (1) · Jung-min Lee (1) · Kristen P Zeligs (1) · Matthew S. Block, MD, PhD (1)
U10CA180868 (3), R01CA276313 (1), UM1CA186709 (1)